Cytosorbents Corporation (CTSO) Receives Daily News Impact Rating of 0.14
Headlines about Cytosorbents Corporation (NASDAQ:CTSO) have trended somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cytosorbents Corporation earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 45.9252831970527 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news articles that may have effected Accern’s scoring:
- Cytosorbents Corporation (CTSO) Stock Price trades 14.28% off from 200- SMA – Voice Of Analysts (analystsbuzz.com)
- Healthcare Stock Buy Signal: Cytosorbents Corporation (CTSO) – Street Observer (press release) (streetobserver.com)
- CytoSorbents Introduces the CytoSorb Therapeutic ECMO(TM) Kit at the 2017 European Society of Intensive Care Medicine Congress (4-traders.com)
- CytoSorbents Introduces the CytoSorb Therapeutic ECMO™ Kit at the 2017 European Society of Intensive Care Medicine Congress (bizjournals.com)
- Cytosorbents Corporation’s (CTSO) Buy Rating Reaffirmed at HC Wainwright (americanbankingnews.com)
Shares of Cytosorbents Corporation (CTSO) traded up 7.83% during mid-day trading on Friday, hitting $6.20. 871,935 shares of the stock were exchanged. Cytosorbents Corporation has a 12 month low of $3.30 and a 12 month high of $6.90. The stock’s market cap is $174.42 million. The stock’s 50 day moving average is $5.14 and its 200-day moving average is $4.78.
Cytosorbents Corporation (NASDAQ:CTSO) last announced its earnings results on Monday, August 7th. The medical research company reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.02. Cytosorbents Corporation had a negative net margin of 80.56% and a negative return on equity of 529.95%. The business had revenue of $3.57 million during the quarter, compared to the consensus estimate of $3.29 million. On average, analysts anticipate that Cytosorbents Corporation will post ($0.27) EPS for the current year.
Several analysts recently commented on the stock. ValuEngine raised shares of Cytosorbents Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, September 6th. HC Wainwright reissued a “buy” rating and set a $13.00 price objective on shares of Cytosorbents Corporation in a research report on Tuesday, September 26th. Maxim Group set a $10.00 price objective on shares of Cytosorbents Corporation and gave the company a “buy” rating in a research report on Monday, July 17th. Aegis reissued a “buy” rating and set a $9.00 price objective on shares of Cytosorbents Corporation in a research report on Tuesday, July 25th. Finally, B. Riley reissued a “buy” rating and set a $11.25 price objective on shares of Cytosorbents Corporation in a research report on Wednesday, August 2nd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $12.71.
Cytosorbents Corporation Company Profile
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.